Senior Machine Learning Engineer, Valo Health
$153-212.4k
Salary is dependent on location
More information about location
Platform for drug development and discovery
Open for applications
Platform for drug development and discovery
101-200 employees
Open for applications
$153-212.4k
Salary is dependent on location
More information about location
101-200 employees
Company mission
To make the drug discovery and development process faster, less expensive, and with a higher probability of success.
Role
Who you are
- Successful candidates must be committed to working with a diverse set of scientists, software engineers, data scientists, and domain experts in ways that cut across traditional industry boundaries in a fast-paced startup environment
- A PhD (or Master’s with experience) in Computer Science, Data Science or related technical field
- Two years of experience applying modern ML/AI techniques to real-world problems with demonstrated business impact
- Strong proficiency in python and modern ML frameworks (PyTorch, Hugging Face)
- An aptitude for learning about new domains and adapting machine learning techniques to impact drug discovery
- Experience with software engineering best practices and an ability to write clean, re-usable code in a collaborative environment
- Experience and interest contributing to all stages of ML development and deployment
- Strong analytical, problem-solving, and communication skills, including the ability to also condense, summarize, and synthesize those results into informative and actionable presentations to less technical audiences
- Strong personal project management skills with demonstrated ability to deliver iterative results and balance tradeoffs between exploratory research and delivering short-term value
What the job involves
- Valo is looking for an experienced Senior Machine Learning Engineer to design and implement novel AI solutions to advance computationally accelerated drug development programs
- You will develop, apply and enhance the capabilities of Valo’s Opal platform to advance real-world, active drug development programs
- Design, develop, test, maintain, and improve an integrated codebase of AI and machine learning tools
- Work with data scientists, researchers, product teams, and other domain experts to build solutions for complex data-oriented problems
- Develop solutions for advancing real-world preclinical discovery programs, tackling problems such as ADME modeling, toxicity prediction, and generative chemistry
Our take
Drug development is a critical component of health care. Reducing costs, improving discovery processes, and accelerating drug development are all critical to success in the drug pipeline. Using human-centric data and ML-anchored computation, Valo Health’s integrated drug development platform, known as Opal, improves outcomes in drug development, by leveraging advanced data analysis.
Drug development entails a variety of steps including molecule discovery, clinical development, and target discovery. With the vast amount of data that is generated, a system like Opal incentivizes investment in outcomes that are more likely to correspond with effective treatments. This reduces the number and expense of clinical trials needed to demonstrate drug effectiveness.
There are a variety of competitors in the data-driven drug discovery field, including insitro, Atomwise, and Exscietia, but this vast market should still offer enough space for Valo Health to grow. In 2021, the company experienced a set-back in the surprise calling off of a merger that would have seen it go public, but despite this has continued to operate well and advance towards its goal of transforming the drug development process.
Freddie
Company Specialist at Welcome to the Jungle
Insights
-23% employee growth in 12 months
Company
Funding (last 2 of 7 rounds)
Nov 2021
$1m
LATE VC
Jul 2021
$33.5m
LATE VC
Total funding: $487.5m
Company benefits
- Medical, Dental, and Vision Insurance
- Flexible Time-off
- 401K
- Corporate Engagement Opportunities with Local Non-Profit Organizations
- Commuter Reimbursement
- Fitness Reimbursement
- Pet Insurance
Company HQ
Back Bay East, Boston, MA
Leadership
Brian Alexander
(CEO)Also a Partner at Flagship Pioneering. Previously SVP of Genentech, CEO of Foundation Medicine and was a n Associate Professor at Harvard Medical School.
Brett Blackman
(COO)Member of the Board of Directors at Stanley Manne Children's Research Institute. Previously Interim Chief Scientific Officer at Omega Therapeutics and was a Strategic R&D Advisor at Ohana Biosciences, Inc.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job